Dear Editors and Reviewers,

Thank you for reviewing our manuscript and providing very insightful comments. According to your valuable suggestions or comments, we have intensively revised our manuscript. Point-by-point response to the reviewer’s comments has been attached.

We hope this revision of this case report will be suitable for publication in World Journal of Clinical Cases.

Sincerely,

Li Zhou, M.D.
Reviewer #1:

Scientific Quality: Grade B (Very good)
Language Quality: Grade B (Minor language polishing)
Conclusion: Accept (General priority)
Specific Comments to Authors: The authors have made an excellent case-report. The manuscript is detailed, and the structure is adequate. As a suggestion, I would propose adding arrows in the figures that highlight the most relevant aspects. The formula used to calculate the eGFR could also be indicated.

Response: Firstly, thank you for taking time to review this case report. 1. We have added arrows in the figures to indicate the relevant aspects. Please see Figure 1B-1D, and Figure 2A-2D. 2. The formula has been supplied in CASE PRESENTATION/Laboratory examination.

Reviewer #2:

Scientific Quality: Grade B (Very good)
Language Quality: Grade B (Minor language polishing)
Conclusion: Minor revision
Specific Comments to Authors: The paper is focused on relevant topic and the aim of the paper is to report that Tolvaptan combined with Edoxaban administration could delay kidney function decline and eliminate the edema caused by the thromboembolism. The manuscript is clear and presented in a well-structured manner. The presentation of the case is well designed and results are reported clearly and appropriate. Tables and figures properly show the data. Would recommend to discuss the setting of neoplasm in PKD or kidney end stage. This is a question due to the macroscopic issues due to the diagnostic issues. This is also relevant in the context of transplant as kidney tumors are one of the most important to be transmitted. Quote as follow and please discuss this topic. - Donor-transmitted cancer in kidney transplant recipients: a systematic review. J Nephrol. 2020 Jun 13. doi: 10.1007/s40620-020-00775-4.

Response: Thank you for your suggestion. Renal cancer risk for PKD or kidney transplantation transmitted cancer has been discussed in the Discussion section.

Reviewer #3:

Scientific Quality: Grade B (Very good)
Language Quality: Grade B (Minor language polishing)
Conclusion: Accept (General priority)
Specific Comments to Authors: None

Response: This case report article has been polished. Thank you.